NNFN Stock Chart & Stats
CHF3.39
CHF0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF2.73 - CHF3.39
Previous CloseN/A
VolumeN/A
Average Volume (3M)250.00
Market Cap
CHF877.55M
Enterprise ValueCHF1.64B
Total Cash (Recent Filing)CHF111.13M
Total Debt (Recent Filing)CHF330.85M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Nov 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding321,544,500
10 Day Avg. Volume250
30 Day Avg. Volume250
Financial Highlights & Ratios
PEG Ratio-3.54
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF6.27Price Target Upside― Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.15
Revenue Forecast (FY)CHF369.37M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sustained multi-year revenue ramp indicates stronger commercial traction and expanding demand for MannKind’s products. Continued top-line growth can improve operating leverage, support reinvestment in the inhalation platform, and strengthen the company’s position over the next several quarters.
Inhaled Product PlatformMannKind’s proprietary Technosphere platform supports multiple inhaled therapies and creates opportunities across products, partnerships, manufacturing, and potential licensing. This platform-based model can provide repeatable development capabilities and broaden revenue sources beyond a single commercial product.
High Gross MarginA high gross margin provides meaningful contribution from each dollar of revenue and creates potential for improved profitability as commercial scale develops. It also gives MannKind greater capacity to fund product support, platform development, and partnership obligations if revenue momentum persists.
Bears Say
Stressed Balance SheetNegative equity and substantial debt leave MannKind with limited financial cushioning if operating performance weakens. The stressed capital structure can restrict strategic flexibility, increase dependence on capital markets, and make future funding requirements more consequential for shareholders.
Free-Cash-Flow BurnThe return to operating and free-cash-flow losses shows that revenue growth has not yet translated into dependable cash generation. Persistent burn would increase liquidity pressure, reduce internally funded investment capacity, and heighten reliance on financing while the balance sheet remains leveraged.
Unstable ProfitabilityProfitability has not proved durable despite the strong revenue ramp and high gross margin. A sizable TTM net loss and very thin operating margin indicate that expenses and other costs are absorbing most gross profit, limiting earnings visibility and the ability to compound capital internally.
MannKind News
NNFN FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was CHF2.73 and its highest was CHF3.39 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is CHF877.55M.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is Nov 10, 2026 which is in 29 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Aug 05, 2026. The company reported -CHF0.05 earnings per share for the quarter, missing the consensus estimate of -CHF0.007 by -CHF0.043.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is -0.05.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 321,544,500 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of -CHF0.05 in its last earnings report, missing expectations of -CHF0.007. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in CH:NNFN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF6.27 (― Upside)
CHF6.27 (― Upside)
Blogger Sentiment
Bullish
CH:NNFN Sentiment 60%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.99%
12-Months-Change
Fundamentals
Return on Equity
78.60%
Trailing 12-Months
Asset Growth
77.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mannkind Corp.
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
NNFN Company Deck
NNFN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple near-term commercial and clinical catalysts, solid top-line growth (15% YoY) and strong operational wins (FURO6 prescriber growth, royalties up 9%, SC Pharma synergies exceeding $20M), alongside meaningful progress on pipeline programs (MNKD-201 Phase 1b and Phase 2 start) and an expanded collaboration with United Therapeutics (ralinepag DPI payment and milestone potential). Short-term challenges include seasonality, field reorganization and inventory transitions that pressured Q1 revenue and contributed to GAAP and non-GAAP losses, plus some formulation and development uncertainty for new DPI programs. Management reiterated full-year FURO6 guidance and expects acceleration in H2 tied to the ReadyFlow auto-injector and Afrezza pediatrics launch, indicating confidence that near-term investments will drive longer-term growth.View all CH:NNFN earnings summaries